Want to see TNON full AI Analyst Report?
TNON Stock Chart & Stats
$1.00
-$0.13(-5.94%)
At close: 4:00 PM EST
$1.00
-$0.13(-5.94%)
Day’s Range― - ―
52-Week Range$0.26 - $2.48
Previous CloseN/A
Volume74.29K
Average Volume (3M)14.07M
Market Cap
$3.29M
Enterprise Value$4.72M
Total Cash (Recent Filing)$4.61M
Total Debt (Recent Filing)$4.88M
Price to Earnings (P/E)―
Beta1.15
Next Earnings
Aug 12, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.33
Shares Outstanding17,375,990
10 Day Avg. Volume12,355,832
30 Day Avg. Volume14,073,318
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.39
Price to Sales (P/S)1.78
P/FCF Ratio-0.64
Enterprise Value/Market Cap1.43
Enterprise Value/Revenue1.02
Enterprise Value/Gross Profit1.59
Enterprise Value/Ebitda-0.41
Forecast
1Y Price Target
$2.63Price Target Upside162.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.85
Revenue Forecast (FY)$6.42M
Bulls Say, Bears Say
Bulls Say
Revenue And Margin ImprovementSustained revenue growth and rising gross margins reflect improving unit economics and early commercial traction. Higher margins (management targets high‑60s to >70% with scale) provide durable operating leverage potential as procedure volumes and product mix scale over the next 2–6 months.
Expanded IP And Product PipelineA growing patent portfolio and multiple pending applications strengthen differentiation and raise barriers to entry. Combined with planned Symmetry Plus enhancements and a third approach pipeline, the IP build supports sustainable competitiveness and licensing or reimbursement leverage over time.
Regulatory Clearance And Lower Per‑procedure Costs510(k) clearance and reusable instrument reclassification reduce adoption friction and recurring procedure costs for hospitals. These structural improvements improve hospital economics, support broader facility uptake, and sustainably enhance gross margins and value proposition to buyers.
Bears Say
Heavy Cash Burn And Negative Free Cash FlowPersistent, large negative operating and free cash flow forces ongoing external financing and constrains strategic optionality. Over a multi‑month horizon this increases dilution risk, limits ability to self‑fund commercialization, and pressures prioritization of near‑term revenue drivers.
Elevated Leverage And Equity ShortfallHigh leverage relative to a modest equity base reduces balance sheet flexibility and raises refinancing risk. The Nasdaq equity deficiency imposes an urgent compliance timeline that can force dilutive financings or operational tradeoffs, elevating medium‑term listing and funding uncertainty.
Small Absolute Scale & Execution FrictionLimited revenue scale means fixed OpEx absorbs disproportionately high costs; hospital approval processes and the need to convert trained physicians into routine users are structural adoption frictions. Execution delays on these fronts can materially slow sustainable margin and profit improvements.
Tenon Medical, Inc. News
TNON FAQ
What was Tenon Medical, Inc.’s price range in the past 12 months?
Tenon Medical, Inc. lowest stock price was $0.26 and its highest was $2.48 in the past 12 months.
What is Tenon Medical, Inc.’s market cap?
Tenon Medical, Inc.’s market cap is $3.29M.
When is Tenon Medical, Inc.’s upcoming earnings report date?
Tenon Medical, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 35 days.
How were Tenon Medical, Inc.’s earnings last quarter?
Tenon Medical, Inc. released its earnings results on May 12, 2026. The company reported -$0.31 earnings per share for the quarter, missing the consensus estimate of -$0.305 by -$0.005.
Is Tenon Medical, Inc. overvalued?
According to Wall Street analysts Tenon Medical, Inc.’s price is currently Undervalued.
Does Tenon Medical, Inc. pay dividends?
Tenon Medical, Inc. does not currently pay dividends.
What is Tenon Medical, Inc.’s EPS estimate?
Tenon Medical, Inc.’s EPS estimate is -0.24.
How many shares outstanding does Tenon Medical, Inc. have?
Tenon Medical, Inc. has 17,375,990 shares outstanding.
What happened to Tenon Medical, Inc.’s price movement after its last earnings report?
Tenon Medical, Inc. reported an EPS of -$0.31 in its last earnings report, missing expectations of -$0.305. Following the earnings report the stock price went down -11.548%.
Which hedge fund is a major shareholder of Tenon Medical, Inc.?
Currently, no hedge funds are holding shares in TNON
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tenon Medical, Inc.
Tenon Medical, Inc., a medical device company, engages in the development of implant for the treatment of severe lower back pain in the United States. The company offers Catamaran SI-Joint Fusion System, an invasive approach to the sacroiliac joint (SI Joint) using a titanium implant for treatment of the most common types of SI Joint disorders that cause lower back pain. It also provides Catamaran Fixation Device which passes through both the axial and sagittal planes of the ilium and sacrum, transfixing the SI Joint along its longitudinal axis. Tenon Medical, Inc. was incorporated in 2012 and is headquartered in Los Gatos, California.
TNON Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed clear progress: strong Q1 revenue (~+90% YoY), record gross profit and a large margin expansion (+24 percentage points), tangible commercial and IP investments, and added financing that extends runway. The company still operates at a net loss with OpEx elevated relative to a small revenue base and relies on successful commercial conversion and upcoming product launches to sustain momentum. Overall, the positives (sharp growth, margin gains, funding, IP and training investments) outweigh the risks, though meaningful execution is required to translate momentum into sustained profitability.View all TNON earnings summariesTNON Stock 12 Month Forecast
Average Price Target
$2.63
▲(162.50% Upside)
Technical Analysis
Strata Skin Sciences
―
Lifeward
―
enVVeno Medical
―
PAVmed
―
Heart Test Laboratories, Inc.
―
Ownership Overview
12.88% Insiders
1.12% Mutual Funds
0.96% Other Institutional Investors
84.43% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---